Gilead Extends Push Into Oncology With Agenus R&D Pact

Allying itself with US biotech Agenus underscores Gilead's oncology ambitions, which incoming CEO-designate Daniel O'Day must make good on.

SyringeClinic
R&D Pact Provides Gilead Options To 3 Agenus immuno-oncology Assets • Source: Shutterstock

More from Deals

More from Business